SkinTE is under clinical development by RegenETP and currently in Phase III for Diabetic Foot Ulcers. According to GlobalData, Phase III drugs for Diabetic Foot Ulcers does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the SkinTE LoA Report. Buy the report here.

Smarter leaders trust GlobalData


Data Insights N

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SkinTE overview

SkinTE is under development for the treatment of diabetic foot ulcers, venous leg ulcers, other chronic wounds, acute or traumatic wounds and burns. It is administered through topical route. The therapeutic candidate is a personalized autologous regenerative therapy being developed based on minimally polarized functional unit (MPFU) technology. 

RegenETP overview

RegenETP, formerly PolarityTE Inc, focuses on developing regenerative treatments and technology that will utilize a patient’s own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. The company’s regenerative tissue product SkinTE provides a barrier to water loss and pathogens, and protects against diverse forms of trauma, including thermal, chemical, and ultraviolet radiation. RegenETP is headquartered in Salt Lake City, Utah, the US.

For a complete picture of SkinTE’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 April 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.